Repligen Corp is a life sciences company focused on developing and manufacturing technologies that optimize bioprocessing for the production of biologics, vaccines, gene therapies, and other advanced therapies. The company provides innovative solutions across key stages of the biopharmaceutical manufacturing process, including upstream and downstream processing, process intensification, and real-time process management.
Repligen's portfolio includes products for filtration, chromatography, fluid management, cell culture supplements, and process analytics. These technologies are designed to improve efficiency, scalability, and product quality for biopharmaceutical developers and contract manufacturing organizations worldwide.
The company serves a broad range of modalities, including monoclonal antibodies, viral vectors, mRNA, plasmid DNA, and emerging therapeutic areas. Repligen is committed to advancing innovation in bioprocessing through continuous technology development and strategic partnerships.
